Cover Image
市場調查報告書

大腸癌肝轉移:開發中產品分析

Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484627
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
大腸癌肝轉移:開發中產品分析 Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 39 Pages
簡介

患有結直腸癌轉移肝臟的患者通常無症狀。腹痛,體重減輕等症狀與末期轉移和預後不良有關。儘管肝臟切除並不是大多數結直腸癌轉移肝患者的主要治療方法,但適當的肝臟切除術是肝結直腸癌轉移患者的標準治療方式。

本報告提供全球各國治療大腸癌肝轉移所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

大腸癌肝轉移;概要

大腸癌肝轉移- 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Alfact Innovation
  • Cellular Biomedicine Group Inc
  • Delcath Systems Inc
  • Gradalis Inc

藥物簡介

暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9700IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017, provides an overview of the Hepatic - Colorectal Metastasis (Oncology) pipeline landscape.

Patients who present with hepatic colorectal metastases are usually asymptomatic. Symptoms such as abdominal pain and weight loss are associated with advanced (high-volume) metastases and a poor prognosis. Although liver resection is not the primary treatment for most patients with hepatic colorectal metastases, appropriate liver resection is the standard of care for treatment of patients with isolated hepatic colorectal metastases.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatic - Colorectal Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic - Colorectal Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatic - Colorectal Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 4 respectively.

Hepatic - Colorectal Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic - Colorectal Metastasis (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hepatic - Colorectal Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatic - Colorectal Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatic - Colorectal Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic - Colorectal Metastasis (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatic - Colorectal Metastasis (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatic - Colorectal Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hepatic - Colorectal Metastasis - Overview
  • Hepatic - Colorectal Metastasis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Hepatic - Colorectal Metastasis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hepatic - Colorectal Metastasis - Companies Involved in Therapeutics Development
  • Alfact Innovation
  • Cellular Biomedicine Group Inc
  • Delcath Systems Inc
  • Gradalis Inc
  • Hepatic - Colorectal Metastasis - Drug Profiles
  • ALF-5755 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CBM-EGFR.1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • contusugene ladenovec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • gemogenovatucel-T - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HSVRbp-450 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • melphalan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hepatic - Colorectal Metastasis - Dormant Projects
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hepatic - Colorectal Metastasis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Hepatic - Colorectal Metastasis - Pipeline by Alfact Innovation, H2 2017
  • Hepatic - Colorectal Metastasis - Pipeline by Cellular Biomedicine Group Inc, H2 2017
  • Hepatic - Colorectal Metastasis - Pipeline by Delcath Systems Inc, H2 2017
  • Hepatic - Colorectal Metastasis - Pipeline by Gradalis Inc, H2 2017
  • Hepatic - Colorectal Metastasis - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Hepatic - Colorectal Metastasis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top